KOS Pharmaceuticals, Inc. engages in the development and commercialization of prescription products for the treatment of chronic cardiovascular, metabolic, and respiratory diseases. Its products include Niaspan for the treatment of mixed lipid disorders; Advicor for the treatment of primary hypercholesterolemia and mixed dyslipidemia in patients previously treated with either component or who require additional lipid modification for LDL and HDL cholesterol, and triglycerides beyond that achieved by the individual components; and Azmacort product, an inhaled corticosteroid that alleviates inflammation in the lungs and is used as prophylactic therapy for the maintenance treatment of asthma. The company’s products also comprise Cardizem LA, a nondihydropyridine calcium channel blocker indicated to treat hypertension and chronic stable angina; Teveten, an angiotensin II receptor blocker also used to treat hypertension alone or in combination with other products; and Teveten HCT, an anti-hypertensive agent combines Teveten and a diuretic for additional blood pressure control. Its products under development include solid-dose drug delivery systems and metered-dose inhalation devices and other device products, as well as it conducts research on respiratory and advanced inhalation delivery. The company markets its products directly through its sales force and copromotion partner in the United States, and through its commercialization partners and license arrangements outside of the United States, Canada, and Japan. Kos Pharmaceuticals has a licensing agreement with SkyePharma plc to jointly develop Flutiform, SkyePharma’s asthma and chronic obstructive pulmonary disease treatment. The company was founded by Michael Jaharis in 1988. The company is based in Cranbury, New Jersey. As of December 12, 2006, KOS Pharmaceuticals, Inc. is a subsidiary of Abbott Laboratories.
Kos Pharmaceuticals Unstoppable
